LUYE PHARMA

2186
1.5451.59% ( -0.025 )
Delay Closed: Nov 16, 16:08:11

Overview

LUYE PHARMA (2186)

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the Un...

Open
1.580
High
1.580
Low
1.535
Prev. Close
1.570
Volume
23.75M
Turnover
36.82M
Avg Price
1.550
Bid/Ask Ratio
-91.27%
Amplitude
2.87%
52wk High
3.250
Volume Ratio
0.50
Turnover Ratio
0.59%
52wk Low
1.535
HK Mkt Cap
6.17B
Market CapHKD
6.17B
P/ETTM
7.70
P/EDynamic
6.86
P/EStatic
--
EPSTTM
0.201
EPSDynamic
0.225
EPSStatic
--
BVPS
4.42
P/B
0.35
HK Shares
3.99B
Dividend YieldTTM
--
DividendTTM
--
Shares
3.99B
Min lot size
500
Currency
HKD

LUYE PHARMA Analyst Rating

View more

Forecast & Rating

Oct 8, 2026
Price forecast
HK$2.8282.68%
Forecast & RatingBuy
2analysts
  • Strong buy50.00%
  • Buy0.00%
  • Hold50.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Luye Pharma surged 9.14% to close at HKD 2.030 on heavy volume, driven by positive Phase II top-line results for LY03015 in tardive dyskinesia (TD). The drug showed significant improvement in LSM at week 24 with a rapid onset by week 6 and a favorable safety profile. The stock opened low at HKD 1.870 and rallied steadily to hit intraday high of HKD 2.030 in the afternoon session, with turnover exceeding HKD 200 million. Financially, net profit surged over 200% YoY in Q3-Q4, while EPS improved to HKD 0.0422, though revenue growth remained single-digit. The price reclaimed the 20-day MA (HKD 1.877), yet YTD declines of 26.71% and a 54.79% gap from the 52-week high of HKD 4.49 persist, with a PB of 0.47x. However, the 60-day MA (HKD 2.328) still looms as overhead resistance.

News